keyword
MENU ▼
Read by QxMD icon Read
search

G-I CANCER

keyword
https://www.readbyqxmd.com/read/29678303/tumor-response-after-long-interval-comparing-5x5gy-radiation-therapy-with-chemoradiation-therapy-in-rectal-cancer-patients
#1
A J M Rombouts, N Hugen, R H A Verhoeven, M A G Elferink, P M P Poortmans, I D Nagtegaal, J H W de Wilt
BACKGROUND: In the era of organ preserving strategies in rectal cancer, insight into the efficacy of preoperative therapies is crucial. The goal of the current study was to evaluate and compare tumor response in rectal cancer patients according to their type of preoperative therapy. METHODS: All rectal cancer patients diagnosed between 2005 and 2014, receiving radiation therapy (RT, 5 × 5Gy; N = 764) or chemoradiation therapy (CRT; N = 5070) followed by total mesorectal excision after an interval of 5-15 weeks were retrieved from the nationwide Netherlands Cancer registry...
March 27, 2018: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29678274/preoperative-mri-evaluation-of-lesion-nipple-distance-in-breast-cancer-patients-thresholds-for-predicting-occult-nipple-areola-complex-involvement
#2
G Mariscotti, M Durando, N Houssami, C M Berzovini, F Esposito, M Fasciano, P P Campanino, D Bosco, R Bussone, A Ala, I Castellano, A Sapino, L Bergamasco, P Fonio, G Gandini
AIM: To identify clinically occult nipple-areola complex (NAC) involvement using preoperative magnetic resonance imaging (MRI), to inform selection of patients eligible for nipple-sparing mastectomy (NSM) or skin-sparing mastectomy (SSM). MATERIAL AND METHODS: This was a retrospective study of 195 patients, who had preoperative breast MRI (February 2011 to January 2017) before undergoing surgical treatments (NSM or SSM) for newly diagnosed breast cancer. Tumour features at MRI (mass or non-mass lesion, diameter, lesion-NAC distance [LND]) and pathology (lesion diameter, histopathological type, receptor status) were recorded, as well as the type of surgery (NSM/SSM) and presence (NAC+) or absence (NAC-) of tumour at intraoperative evaluation of retroareolar tissue...
April 17, 2018: Clinical Radiology
https://www.readbyqxmd.com/read/29678145/evaluation-of-pet-and-laparoscopy-in-staging-advanced-gastric-cancer-a-multicenter-prospective-study-plastic-study
#3
H J F Brenkman, E C Gertsen, E Vegt, R van Hillegersberg, M I van Berge Henegouwen, S S Gisbertz, M D P Luyer, G A P Nieuwenhuijzen, J J B van Lanschot, S M Lagarde, W O de Steur, H H Hartgrink, J H M B Stoot, K W E Hulsewe, E J Spillenaar Bilgen, M J van Det, E A Kouwenhoven, D L van der Peet, F Daams, J W van Sandick, N C T van Grieken, J Heisterkamp, B van Etten, J W Haveman, J P Pierie, F Jonker, A Y Thijssen, E J T Belt, P van Duijvendijk, E Wassenaar, H W M van Laarhoven, F J Wessels, N Haj Mohammad, H F van Stel, G W J Frederix, P D Siersema, J P Ruurda
BACKGROUND: Initial staging of gastric cancer consists of computed tomography (CT) and gastroscopy. In locally advanced (cT3-4) gastric cancer, fluorodeoxyglucose positron emission tomography with CT (FDG-PET/CT or PET) and staging laparoscopy (SL) may have a role in staging, but evidence is scarce. The aim of this study is to evaluate the impact and cost-effectiveness of PET and SL in addition to initial staging in patients with locally advanced gastric cancer. METHODS: This prospective observational cohort study will include all patients with a surgically resectable, advanced gastric adenocarcinoma (cT3-4b, N0-3, M0), that are scheduled for treatment with curative intent after initial staging with gastroscopy and CT...
April 20, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29676359/molecular-genetics-of-bcr-abl1-negative-myeloproliferative-neoplasms-in-india
#4
Nikhil Rabade, P G Subramanian, Rohan Kodgule, Goutham Raval, Swapnali Joshi, Shruti Chaudhary, Russel Mascarenhas, Prashant Tembhare, Sumeet Gujral, Nikhil Patkar
Introduction: Over the past decade, we have moved on from a predominantly morphological and clinical classification of myeloproliferative neoplasms (MPN) to a more evolved classification that accounts for the molecular heterogeneity that is unique to this subgroup of hematological malignancies. This usually incorporates mutations in Janus kinase 2 (JAK2), MPL, and calreticulin (CALR) genes. In this manuscript, we report the frequency of these mutations in a cohort of Indian patients at a tertiary cancer center...
April 2018: Indian Journal of Pathology & Microbiology
https://www.readbyqxmd.com/read/29676345/bilateral-subcapsular-orchiectomy-versus-bilateral-total-orchiectomy-comparison-of-the-quality-of-life-post-orchiectomy
#5
Dubem Ejikeme Orakwe, Kehinde Habeeb Tijani, Emmauel Ajibola Jeje, Moses Adebisi Ogunjimi, Wale Ojewola Rufus, Taiwo Opeyemi Alabi
Objective: Bilateral subcapsular orchiectomy (BSO) is said to be more aesthetic and psychologically satisfying when compared to bilateral total orchiectomy (BTO). This study compared the quality of life (QoL) of men with advanced prostate cancer who had BTO to those who had BSO, with an emphasis on their perception of self or identity as a man. Subjects and Methods: Sixty-one patients with advanced prostate cancer opting for bilateral orchiectomy were recruited...
January 2018: Nigerian Postgraduate Medical Journal
https://www.readbyqxmd.com/read/29674704/mek-inhibitors-overcome-resistance-to-bet-inhibition-across-a-number-of-solid-and-hematologic-cancers
#6
Anastasia Wyce, Jeanne J Matteo, Shawn W Foley, Daniel J Felitsky, Satyajit R Rajapurkar, Xi-Ping Zhang, Melissa C Musso, Susan Korenchuk, Natalie O Karpinich, Kathryn M Keenan, Melissa Stern, Lijoy K Mathew, Charles F McHugh, Michael T McCabe, Peter J Tummino, Ryan G Kruger, Christopher Carpenter, Olena Barbash
BET inhibitors exhibit broad activity in cancer models, making predictive biomarkers challenging to define. Here we investigate the biomarkers of activity of the clinical BET inhibitor GSK525762 (I-BET; I-BET762) across cancer cell lines and demonstrate that KRAS mutations are novel resistance biomarkers. This finding led us to combine BET with RAS pathway inhibition using MEK inhibitors to overcome resistance, which resulted in synergistic effects on growth and survival in RAS pathway mutant models as well as a subset of cell lines lacking RAS pathway mutations...
April 20, 2018: Oncogenesis
https://www.readbyqxmd.com/read/29674426/association-of-polygenic-risk-score-with-the-risk-of-chronic-lymphocytic-leukemia-and-monoclonal-b-cell-lymphocytosis
#7
Geffen Kleinstern, Nicola J Camp, Lynn R Goldin, Celine M Vachon, Claire M Vajdic, Silvia de Sanjose, J Brice Weinberg, Yolanda Benavente, Delphine Casabonne, Mark Liebow, Alexandra Nieters, Henrik Hjalgrim, Mads Melbye, Bengt Glimelius, Hans-Olov Adami, Paolo Boffetta, Paul Brennan, Marc Maynadie, James McKay, Pier Luigi Cocco, Tait D Shanafelt, Timothy G Call, Aaron Norman, Curtis Hanson, Dennis Robinson, Kari G Chaffee, Angela R Brooks-Wilson, Alain Monnereau, Jacqueline Clavel, Martha Glenn, Karen Curtin, Lucia Conde, Paige M Bracci, Lindsay M Morton, Wendy Cozen, Richard K Severson, Stephen J Chanock, John J Spinelli, James B Johnston, Nathaniel Rothman, Christine F Skibola, Jose F Leis, Neil E Kay, Karin E Smedby, Sonja I Berndt, James R Cerhan, Neil Caporaso, Susan L Slager
Inherited loci have been found to be associated with risk of chronic lymphocytic leukemia (CLL). A combined polygenic risk score (PRS) of representative single nucleotide polymorphisms (SNPs) from these loci may improve risk prediction over individual SNPs. Herein, we evaluated the association of a PRS with CLL risk and its precursor, monoclonal B-cell lymphocytosis (MBL). We assessed its validity and discriminative ability in an independent sample and evaluated effect modification and confounding by family history (FH) of hematological cancers...
April 19, 2018: Blood
https://www.readbyqxmd.com/read/29673839/development-of-a-macrophage-targeting-and-phagocytosis-inducing-bio-nanocapsule-based-nanocarrier-for-drug-delivery
#8
Hao Li, Kenji Tatematsu, Masaharu Somiya, Masumi Iijima, Shun' Ichi Kuroda
Macrophage hyperfunction or dysfunction is tightly associated with various diseases, such as osteoporosis, inflammatory disorder, and cancers. However, nearly all conventional drug delivery system (DDS) nanocarriers utilize endocytosis for entering target cells; thus, the development of macrophage-targeting and phagocytosis-inducing DDS nanocarriers for treating these diseases is required. In this study, we developed a hepatitis B virus (HBV) envelope L particle (i.e., bio-nanocapsule (BNC)) outwardly displaying a tandem form of protein G-derived IgG Fc-binding domain and protein L-derived IgG Fab-binding domain (GL-BNC)...
April 16, 2018: Acta Biomaterialia
https://www.readbyqxmd.com/read/29673642/hyperthermia-mediated-drug-delivery-induces-biological-effects-at-the-tumor-and-molecular-levels-that-improve-cisplatin-efficacy-in-triple-negative-breast-cancer
#9
Michael Dunne, Yannan N Dou, Danielle M Drake, Tara Spence, Sávio M L Gontijo, Peter G Wells, Christine Allen
Triple negative breast cancer is an aggressive disease that accounts for at least 15% of breast cancer diagnoses, and a disproportionately high percentage of breast cancer related morbidity. Intensive research efforts are focused on the development of more efficacious treatments for this disease, for which therapeutic options remain limited. The high incidence of mutations in key DNA repair pathways in triple negative breast cancer results in increased sensitivity to DNA damaging agents, such as platinum-based chemotherapies...
April 16, 2018: Journal of Controlled Release: Official Journal of the Controlled Release Society
https://www.readbyqxmd.com/read/29673125/major-pathologic-response-and-rad51-predict-survival-in-lung-cancer-patients-receiving-neoadjuvant-chemotherapy
#10
Apar Pataer, Ruping Shao, Arlene M Correa, Carmen Behrens, Jack A Roth, Ara A Vaporciyan, Ignacio I Wistuba, Stephen G Swisher
In a previous study, we determined that major pathologic response (MPR) as indicated by the percentage of residual viable tumor cells predicted overall survival (OS) in patients with non-small-cell lung cancer (NSCLC) who received neoadjuvant chemotherapy. In this study, we assessed whether two genes and five protein biomarkers could predict MPR and OS in 98 patients with NSCLC receiving neoadjuvant chemotherapy. We collected formalin-fixed, paraffin-embedded specimens of resected NSCLC tumors from 98 patients treated with neoadjuvant chemotherapy...
April 19, 2018: Cancer Medicine
https://www.readbyqxmd.com/read/29671080/-lutetium-177-psma-radioligand-therapy-consensus-within-the-framework-of-gkv-funded-care-between-the-university-hospitals-in-aachen-bonn-d%C3%A3-sseldorf-essen-and-cologne-and-the-mdk-nordrhein
#11
REVIEW
H Ahmadzadehfar, P Albers, A Bockisch, M Boegemann, C Böhme, W Burchert, M Dietlein, A Drzezga, U Fabry, G Feldmann, A Heidenreich, A Heinzel, K Herrmann, A Heyll, C Höhling, C Kreuzer, D Laufer, R Mengel, F M Mottaghy, H-W Müller, S C Müller, E Ost, K Rahbar, W Reifenhäuser, M Schäfers, C Schlenkhoff, M Schmidt, I Schmidt-Wolf, C Wildenhain, B Zimmer, M Essler
In the last 3 years, Lutetium-177 prostate-specific membrane antigen radioligand therapy (Lu-177-PSMA-RLT) has received increasing attention in nuclear medicine as a new form of treatment for castration-resistant metastatic prostate cancer. This therapy combines the radionuclide Lutetium-177, which has been therapeutically used in nuclear medicine for many years, with a molecular target of the transmembrane prostate-specific membrane antigen expressed by prostate cancer cells. Since there are no prospective randomized studies on Lu-177-PSMA-RLT and the question of reimbursement has repeatedly been the subject of review by the MDK Nordrhein (Medischenische Dienst der Krankenversicherung), there was a desire because of the increasing number of patients being treated to clarify under which circumstances Lu-177-PSMA-RLT can be reimbursed by German statutory health insurance...
April 18, 2018: Der Urologe. Ausg. A
https://www.readbyqxmd.com/read/29670092/apr-246-reactivates-mutant-p53-by-targeting-cysteines-124-and-277
#12
Qiang Zhang, Vladimir J N Bykov, Klas G Wiman, Joanna Zawacka-Pankau
The TP53 tumor suppressor gene is frequently inactivated in human tumors by missense mutations in the DNA binding domain. TP53 mutations lead to protein unfolding, decreased thermostability and loss of DNA binding and transcription factor function. Pharmacological targeting of mutant p53 to restore its tumor suppressor function is a promising strategy for cancer therapy. The mutant p53 reactivating compound APR-246 (PRIMA-1Met ) has been successfully tested in a phase I/IIa clinical trial. APR-246 is converted to the reactive electrophile methylene quinuclidinone (MQ), which binds covalently to p53 core domain...
April 18, 2018: Cell Death & Disease
https://www.readbyqxmd.com/read/29669584/mri-based-response-patterns-during-neoadjuvant-chemotherapy-can-predict-pathological-complete-response-in-patients-with-breast-cancer
#13
Briete Goorts, Kelly M A Dreuning, Janneke B Houwers, Loes F S Kooreman, Evert-Jan G Boerma, Ritse M Mann, Marc B I Lobbes, Marjolein L Smidt
BACKGROUND: The main purpose was to investigate the correlation between magnetic resonance imaging (MRI)-based response patterns halfway through neoadjuvant chemotherapy and immunotherapy (NAC) and pathological tumor response in patients with breast cancer. Secondary purposes were to compare the predictive value of MRI-based response patterns measured halfway through NAC and after NAC and to measure interobserver variability. METHODS: All consecutive patients treated with NAC for primary invasive breast cancer from 2012 to 2015 and who underwent breast MRI before, halfway through (and after) NAC were included...
April 18, 2018: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/29668600/chilean-gastric-cancer-task-force-a-study-protocol-to-obtain-a-clinical-and-molecular-classification-of-a-cohort-of-gastric-cancer-patients
#14
Gareth I Owen, Mauricio P Pinto, Ignacio N Retamal, María F Fernádez, Betzabe Cisternas, Sebastian Mondaca, Cesar Sanchez, Hector Galindo, Bruno Nervi, Carolina Ibañez, Francisco Acevedo, Jorge Madrid, José Peña, Maria Loreto Bravo, Maria Jose Maturana, Miguel Cordova-Delgado, Diego Romero, Nathaly de la Jara, Javiera Torres, Maria Rodriguez-Fernandez, Manuel Espinoza, Carlos Balmaceda, Matías Freire, Valentina Gárate-Calderón, Fernando Crovari, Paula Jimenez-Fonseca, Alberto Carmona-Bayonas, Ariel Zwenger, Ricardo Armisen, Alejandro H Corvalan, Marcelo Garrido
Gastric cancer (GC) is the world's second-leading cause of neoplastic mortality. Genetic alterations, response to treatments, and mortality rates are highly heterogeneous across different regions. Within Latin America, GC is the leading cause of cancer death in Chile, affecting 17.6 per 100,000 people and causing >3000 deaths/y. Clinical outcomes and response to "one size fits all" therapies are highly heterogeneous and thus a better stratification of patients may aid cancer treatment and response...
April 2018: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29667768/quinazoline-based-hydroxamic-acids-design-synthesis-and-evaluation-of-histone-deacetylase-inhibitory-effects-and-cytotoxicity
#15
Doan Thanh Hieu, Duong Tien Anh, Hai Pham-The, Le-Thi-Thu Huong, Eun Jae Park, Jeong Eun Choi, Jong Soon Kang, Sang-Bae Han, Phan Thi Phuong Dung, Nguyen-Hai Nam
In our search for novel histone deacetylases inhibitors, we have designed and synthesized a series of novel hydroxamic acids and N-hydroxybenzamides incorporating quinazoline heterocycles (4a-i, 6a-i). Bioevaluation showed that these quinazoline-based hydroxamic acids and N-hydroxybenzamides were potently cytotoxic against three human cancer cell lines (SW620, colon; PC-3, prostate; NCI-H23, lung). In term of cytotoxicity, several compounds, e.g. 4g, 4c, 4g-i, 6c, and 6h, displayed from 5- up to 10-fold higher potency than SAHA (suberoylanilidehydroxamic acid, vorinostat)...
April 18, 2018: Chemistry & Biodiversity
https://www.readbyqxmd.com/read/29667662/camel-milk-attenuates-methotrexate-induced-kidney-injury-via-activation-of-pi3k-akt-enos-signaling-and-intervention-with-oxidative-aberrations
#16
Hany H Arab, Samir A Salama, Ibrahim A Maghrabi
Methotrexate (MTX) is a classical chemotherapeutic agent with nephrotoxicity as the most disturbing adverse effect. So far, its underlying molecular mechanisms, particularly PI3K/Akt/eNOS transduction, are inadequately explored. Several antioxidant modalities have been characterized to ameliorate MTX-induced renal injury. In this regard, Camel milk (CM) is a natural product with recognized antioxidant and anti-inflammatory features. Thus, the current study aimed to investigate the potential ameliorating effects of CM in MTX-induced kidney injury in rats...
April 18, 2018: Food & Function
https://www.readbyqxmd.com/read/29667586/drug-drug-interactions-with-aprepitant-in-antiemetic-prophylaxis-for-chemotherapy
#17
R Schoffelen, A G Lankheet, C M L van Herpen, J J M van der Hoeven, I M E Desar, C Kramers
In the current guidelines to prevent hemotherapyinduced nausea and vomiting, multiple antiemetic drugs are administered simultaneously. In patients who receive highly emetogenic chemotherapy, aprepitant, an NK1-receptor antagonist, is combined with ondansetron and dexamethasone. Aprepitant can influence the pharmacokinetics of other drugs, as it is an inhibitor and inducer of CYP3A4. Some anticancer drugs and other co-medication frequently used in cancer patients are CYP3A4 or CYP29C substrates. We give an overview of the metabolism and current data on clinically relevant drug-drug interactions with aprepitant during chemotherapy...
April 2018: Netherlands Journal of Medicine
https://www.readbyqxmd.com/read/29667555/synthesis-cytotoxicity-and-antioxidant-activity-of-new-analogues-of-rc-121-synthetic-derivatives-of-somatostatin
#18
Diana Wesselinova, Emilia D Naydenova, S Staykova, I G Goshev, L Vezenkov
BACKGROUND: Based on the structure of RC-121 (D-Phe-c (Cys-Tyr-D-Trp-Lys-Val-Cys)-Thr-NH2, - synthetic derivatives of somatostatin), some analogs were synthesized and tested for in vitro cytotoxic and antioxidant activity. OBJECTIVES: The new analogs were modifyed at position 5 with Dap (diaminopropanoic acid), Dab (diaminobutanoic acid) and Orn and at position 6 with the unnatural amino acids Tle (t-leucine). METHODS: The in vitro cytotoxic effects of the substances were investigated against a panel of human tumor cell lines HT-29 (human colorectal cancer cell line), MDA-MB-23 (human breast cancer cell line), Hep G-2 (human hepatocellular carcinoma cell line) and HeLa (cervical cancer cell line)...
April 17, 2018: Anti-cancer Agents in Medicinal Chemistry
https://www.readbyqxmd.com/read/29667385/chance-of-reimbursement-for-add-on-therapies-in-poland-and-in-the-world-review-of-the-reimbursement-recommendations
#19
Ewa Borowiack, Magdalena Marzec, Anna Nowotarska, Joanna Jarosz, Agata Orkisz, Patrycja Prząda-Machno
INTRODUCTION: Oncology drugs combined with standard therapies (so-called add-on therapies, e.g. bevacizumab, palbociclib) often receive negative recommendations regarding the legitimacy of public financing, issued by government agencies responsible for their assessment, i.e. health technology assessment agencies. The aim of the study was to estimate the scale of the problem related to the reimbursement of add-on therapies used in the treatment of breast and genitourinary cancers in Poland and in the world...
2018: Przegla̧d Epidemiologiczny
https://www.readbyqxmd.com/read/29664794/positive-surgical-margins-in-favorable-stage-differentiated-thyroid-cancer
#20
Catherine E Mercado, Peter A Drew, Christopher G Morris, Peter T Dziegielewski, William M Mendenhall, Robert J Amdur
OBJECTIVE: The significance of positive margin in favorable-stage well-differentiated thyroid cancer is controversial. We report outcomes of positive-margin patients with a matched-pair comparison to a negative-margin group. MATERIALS AND METHODS: A total of 25 patients with classic-histology papillary or follicular carcinoma, total thyroidectomy +/- node dissection, stage T1-3N0-1bM0, positive surgical margin at primary site, adjuvant radioactive iodine (I-131), and age older than 18 years were treated between 2003 and 2013...
April 16, 2018: American Journal of Clinical Oncology
keyword
keyword
45893
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"